# Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer

> **NCT03044613** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 32 (actual)

## Conditions studied

- Gastric Cancer
- Esophageal Cancer
- GastroEsophageal Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Relatlimab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT03044613
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-07-11
- **Primary completion:** 2027-03
- **Final completion:** 2027-08
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03044613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03044613, "Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03044613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*